PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-0.08
Negative P/E while Drug Manufacturers - Specialty & Generic median is -8.36. Seth Klarman would scrutinize path to profitability versus peers.
1.85
P/S less than half the Drug Manufacturers - Specialty & Generic median of 9.69. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
0.28
P/B less than half the Drug Manufacturers - Specialty & Generic median of 1.15. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.28
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 1.15. Joel Greenblatt would investigate if this discount is justified.
-304.55%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -2.99%. Seth Klarman would investigate path to profitability.
No Data
No Data available this quarter, please select a different quarter.